Cell Function
Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies
Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment
UnitedHealthcare CEO Brian Thompson Fatally Shot in Targeted Attack Outside New York City Hotel
UnitedHealthcare, CEO Brian Thompson, targeted killing, New York City, hotel shooting, investor meeting
Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs
Blue Earth Therapeutics, Series A financing, radiohybrid RLTs, Phase II studies, targeted therapies, lutetium, alpha emitter.
Revolution Medicines Advances in Pancreatic Cancer Treatment with RMC-6236 and RMC-9805
Revolution Medicines, RMC-6236, RMC-9805, pancreatic cancer, RAS inhibitors, targeted therapies, clinical trials
Nura Bio Secures $68 Million Funding for Neuroprotective SARM1 Inhibitor Development
Nura Bio, neuroprotective SARM1 inhibitor, $68M funding, pharmaceutical development, neuroprotection
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Bayer’s Transformation Accelerates with 3,200 Job Cuts in 2024
Bayer, transformation, job cuts, 2024, Bill Anderson, pharmaceutical industry
FDA Rejects Rocket Pharmaceuticals’ Gene Therapy for Ultra-Rare Immune Disease Over Manufacturing Concerns
FDA, Rocket Pharmaceuticals, Gene Therapy, Leukocyte Adhesion Deficiency-I (LAD-I), Manufacturing Concerns
FDA Rejects Rocket Pharmaceuticals’ Gene Therapy for Ultra-Rare Immune Disease, Requests Additional Manufacturing Information
FDA, Rocket Pharmaceuticals, Gene Therapy, Leukocyte Adhesion Deficiency-I (LAD-I), Manufacturing Information, Complete Response Letter
Merck KGaA Discontinues Xevinapant Program in Locally Advanced Head and Neck Cancer Due to Phase III Trial Failure
Merck KGaA, xevinapant, Phase III trial, head and neck cancer, TrilynX study, X-Ray Vision study, oncology pipeline, apoptosis proteins inhibitor